Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 275 of 1631 entries
View as:

Aflibercept Injection Into the Vitreous Body of the Eye: Study to Learn More About Patient Relevant Outcomes, Real World Treatment Patterns and How Well the Treatment Works for Patients Suffering From Abnormal Growth of New Blood Vessels Under the Retina.

Phase: N/A Priority: Normal
NCT ID: NCT03714308 Org: User:
Start: 01/28/19 End: 05/12/23 Due: 05/12/24

Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

Phase: N/A Priority: Normal
NCT ID: NCT03350295 Org: User:
Start: 06/14/18 End: 12/14/18 Due: 12/14/19

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Phase: N/A Priority: Normal
NCT ID: NCT05350189 Org: User:
Start: 11/03/22 End: 04/27/23 Due: 04/27/24

PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn

Phase: N/A Priority: Normal
NCT ID: NCT04256993 Org: User:
Start: 02/15/20 End: 06/01/21 Due: 06/01/22

Imaging Study to Compare Effects of Darolutamide and Enzalutamide With Respect to Placebo on the Blood Flow in the Brain in Healthy Male Volunteers.

Phase: N/A Priority: Normal
NCT ID: NCT03704519 Org: User:
Start: 10/23/18 End: 11/05/19 Due: 11/05/20

Clinical Study to Evaluate the Maximum Tolerated Dose of BAY1000394 When Given Together With Chemotherapy and the Effectiveness of This Combination Treatment in Shrinking a Specific Type of Lung Tumors (Small Cell Lung Cancer)

Phase: N/A Priority: Normal
NCT ID: NCT01573338 Org: User:
Start: 02/25/13 End: 06/23/16 Due: 06/23/17

EffectiveNess of Low Dose Aspirin in GastrointEstinal Cancer Prevention - Taiwan

Phase: N/A Priority: Normal
NCT ID: NCT03579732 Org: User:
Start: 06/29/18 End: 09/30/19 Due: 09/30/20

Analysis of the Potential Savings of Rivaroxaban Events Versus Vitamin K Antagonists Events

Phase: N/A Priority: Normal
NCT ID: NCT03462446 Org: User:
Start: 06/01/15 End: 05/01/16 Due: 05/01/17

A Study to Learn More About the Use of Aflibercept in Routine Medical Practice in Japanese Participants With Neovascular Age-related Macular Degeneration and Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT06929143 Org: User:
Start: 04/14/25 End: 04/01/27 Due: 04/01/28

Evaluation of the Irritation Potential of Sunscreen Products in Human Eyes

Phase: N/A Priority: Normal
NCT ID: NCT02854137 Org: User:
Start: 10/14/15 End: 10/14/15 Due: 10/14/16

Sun Protection Factor Assay

Phase: N/A Priority: Normal
NCT ID: NCT02822339 Org: User:
Start: 06/23/16 End: 06/29/16 Due: 06/29/17

Proportion of Hysterectomy After Female Sterilization

Phase: N/A Priority: Normal
NCT ID: NCT02532361 Org: User:
Start: 08/31/15 End: 12/31/15 Due: 12/31/16

18850 - Human Photoallergy Test

Phase: N/A Priority: Normal
NCT ID: NCT02751463 Org: User:
Start: 05/09/16 End: 07/01/16 Due: 07/01/17

An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States

Phase: N/A Priority: Normal
NCT ID: NCT06608212 Org: User:
Start: 10/09/24 End: 06/30/25 Due: 06/30/26

Treatment of Venous Thromboembolism (VTE) With Either Rivaroxaban or Current Standard of Care Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02210819 Org: User:
Start: 06/27/14 End: 01/20/17 Due: 01/20/18

1404003_OpenPsori.PlaqueTest to Eval.Eff.of Diff.Comp. to Mapracorat

Phase: N/A Priority: Normal
NCT ID: NCT03399526 Org: User:
Start: 02/11/13 End: 05/31/13 Due: 05/31/14

Treatment of Patients With Acute Sinusitis

Phase: N/A Priority: Normal
NCT ID: NCT00930488 Org: User:
Start: 03/31/07 End: 12/31/08 Due: 12/31/09

A Phase IIb Study to Investigate the Efficacy and Tolerability of Cinaciguat (150 µg/h, 100 µg/h, 50 µg/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Phase: N/A Priority: Normal
NCT ID: NCT01064037 Org: User:
Start: 04/30/10 End: 03/31/11 Due: 03/31/12

Non-interventional Observation of Practical Implementation, Efficacy and Safety of Continuous Infusion With KOGENATE Bayer in Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00922597 Org: User:
Start: 08/31/08 End: 09/30/11 Due: 09/30/12

Efficacy and Safety of CIPRO XR Versus CIPRO IR in Patients With Complicated Urinary Tract Infections

Phase: N/A Priority: Normal
NCT ID: NCT00668122 Org: User:
Start: 03/31/04 End: 01/31/06 Due: 01/31/07

Atrial Fibrillation Patient Preference Study

Phase: N/A Priority: Normal
NCT ID: NCT02611635 Org: User:
Start: 02/02/16 End: 02/16/17 Due: 02/16/18

Study to Gather Information on the Influence of BAY1817080 on the Electrical Activity of the Heart Recorded by an Electrocardiogram in Healthy Male and Female Participants

Phase: N/A Priority: Normal
NCT ID: NCT04423744 Org: User:
Start: 06/18/20 End: 01/21/21 Due: 01/21/22

BAY43-9006 - Phase II in Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00101400 Org: User:
Start: 02/29/04 End: 01/31/08 Due: 01/31/09

A Phase IIb Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 µg/h, 10 µg/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)

Phase: N/A Priority: Normal
NCT ID: NCT01067859 Org: User:
Start: 03/31/10 End: 11/30/10 Due: 11/30/11

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

Phase: N/A Priority: Normal
NCT ID: NCT04435626 Org: User:
Start: 09/14/20 End: 06/14/24 Due: 06/14/25